Retatrutide is a novel triple agonist of the GLP-1/GIP/GCGR Glucose-dependent Insulinotropic Polypeptide, Glucagon-Like Peptide-1 and glucagon receptors GCGR. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively. Considered one of the most advanced weight loss compounds ever created. If you have been using Semaglutide and have seemingly stalled out, Retatrutide will help kickstart your weight loss journey once more.
 
Why Retatrutide is different and how it works.
Retatrutide’s GCG (glucagon) component functions as a glucagon receptor agonist, designed to increase energy expenditure and stimulate the breakdown of stored fat (lipolysis). By activating this receptor, retatrutide accelerates the body's metabolic rate, promoting a higher caloric burn and fat loss, which contributes to its enhanced weight-loss efficacy compared to GLP-1/GIP-only medications. 
Key Functions of the GCG Component:
Increased Energy Expenditure: The GCG component stimulates metabolism and thermogenesis, essentially causing the body to burn more calories, including during rest.
Enhanced Lipolysis: It acts as a catabolic agent, promoting the breakdown of stored adipose tissue (fat) to be used for energy.
Weight Loss Amplification: By acting alongside the GIP and GLP-1 components (making it a "triple G" agonist), the GCG component provides a unique mechanism that drives greater fat reduction. 
While natural glucagon increases blood sugar, the GCG component in retatrutide is balanced by the simultaneous activation of GLP-1 and GIP receptors, which manage glucose levels and reduce appetite, respectively. This combination aims to optimize weight loss (up to 24.2% in trials) and metabolic health.